First described at the turn of the 20th century for repairing retinal detachments (RDs), intravitreal injections (IVIs) have become the most widely performed procedures in the ophthalmic field.1 IVIs with anti–vascular endothelial growth factor (VEGF) agents have significantly improved management and visual prognosis of angiogenic retinal diseases, including neovascular age-related macular degeneration, diabetic macular edema, retinal vein occlusion, proliferative diabetic retinopathy, choroidal neovascularization, and other visual impairments.2 Here, VEGFA is linked to wet macular degeneration.